Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
79,108,788
-
Total 13F shares
-
34,713,391
-
Share change
-
-431,579
-
Total reported value
-
$298,534,855
-
Price per share
-
$8.60
-
Number of holders
-
87
-
Value change
-
-$5,432,193
-
Number of buys
-
56
-
Number of sells
-
26
Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q4 2023
As of 31 Dec 2023,
Mineralys Therapeutics, Inc. - Common Stock (MLYS) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,713,391 shares.
The largest 10 holders included
Catalys Pacific, LLC, Samsara BioCapital, LLC, RA CAPITAL MANAGEMENT, L.P., ADAMS STREET PARTNERS LLC, BRAIDWELL LP, SR ONE CAPITAL MANAGEMENT, LP, BlackRock Inc., Rock Springs Capital Management LP, Laurion Capital Management LP, and VANGUARD GROUP INC.
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.